Nuo Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update
Key Highlights
- ➤Q3 revenue $1.9 million, up 80% year over year
- ➤Nine-month revenue $4.9 million, up 123% year over year
- ➤Aurix wound care revenue increased approximately 17% sequentially
- ➤2027 OPPS G0465 reimbursement rises 7% to approximately $2,257
- ➤Final $325,000 loan funding lifted total borrowings to $2,000,000
Expert Statements
David Jorden, Chief Executive and Financial Officer of Nuo Therapeutics
“As many wound care market participants have commented, the broader wound care space remains unsettled resulting from the dramatic January change to reimbursement economics for skin substitutes/grafts which remained unchanged in the final 2027 rulings mentioned above.”
David Jorden, Chief Executive and Financial Officer of Nuo Therapeutics
“We have also observed a shift of patients and wound care volumes back to hospital-based settings and enjoyed our highest quarter ever of Aurix revenues in the hospital setting,”
David Jorden, Chief Executive and Financial Officer of Nuo Therapeutics
“Since this year’s first quarter, our HOPD Aurix sales as a percentage of total wound care sales has more than doubled.”
David Jorden, Chief Executive and Financial Officer of Nuo Therapeutics
“The economics in hospital settings are strong, and we will continue to pursue and emphasize growth opportunities in this segment.”
David Jorden, Chief Executive and Financial Officer of Nuo Therapeutics
“We remain confident that autologous PRP and Aurix in particular are well positioned for continued long term attractive growth.”
David Jorden, Chief Executive and Financial Officer of Nuo Therapeutics
“As a business, we are prioritizing both reaching the revenue level required for operational breakeven and assessing opportunities to strengthen our capital structure to support Nuo’s next stage of growth.”
David Jorden, Chief Executive and Financial Officer of Nuo Therapeutics
“The funding of the secured notes under the loan agreement in several tranches this year was done with these priorities in mind.”
HOUSTON, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial-stage medical device company focused on developing and marketing regenerative therapies for chronic wound care, announced financial results for the third quarter ended September 30, 2026 and provided an operational and business update.
Third Quarter and First Nine Months 2026 Financial Summary * Total revenues of approximately $1.9 million and $4.9 million for the third quarter 2026 and first nine months of 2026, respectively, increased 80% and 123%, respectively, versus the comparable 2025 periods. * Total product revenues in the third quarter increased 5% sequentially versus the second quarter 2026 with Aurix wound care revenues increasing approximately 17% sequentially which is the same average sequential growth rate over the past six quarters for Aurix wound care revenues. * Third quarter net operating loss of approximately $374,000 improved by approximately $166,000 compared to third quarter 2025 while increasing approximately $208,000 sequentially versus the second quarter. The sequential increase primarily reflected higher stock-based compensation, credit loss provision expense, and more than $100,000 of elevated regulatory costs associated with component supply matters. * Subsequent to quarter end, final funding of $325,000 was received under the loan agreement with total borrowings established at $2,000,000. Operational and Business Update * Received $250,000 reimbursement fee milestone pursuant to the 2025 distribution agreement with Smith+Nephew. * Final Medicare OPPS (Outpatient Prospective Payment System) reimbursement ruling recently released for calendar 2027 with the per treatment G0465 national average reimbursement increasing to approximately $2,257 or 7% from 2026 with positive pricing actions for Aurix anticipated next year. * Medicare’s PFS (Physician Fee Schedule) ruling established a G0465 national average reimbursement of approximately $1,020 in 2027 or a decrease of approximately 4%. * Expansion of coverage and processing of G0465 claims for nursing home treatments (Medicare Place of Service 32) effective January 1, 2027 is expected to be positive for future growth. “As many wound care market participants have commented, the broader wound care space remains unsettled resulting from the dramatic January change to reimbursement economics for skin substitutes/grafts which remained unchanged in the final 2027 rulings mentioned above,” commented David Jorden, Nuo’s Chief Executive and Financial Officer.
Get started
Create a free account to read the full story.
